John Lawrence Yu

US Patent:

6774119, Aug 10, 2004

Filed:

Apr 26, 1999

Appl. No.:

09/299817

Inventors:

Steven L. Wechsler - Westlake Village CA
Anthony B. Nesburn - Malibu CA
John S. Yu - Los Angeles CA
Keith L. Black - Los Angeles CA

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A61K 4800

US Classification:

514 44, 4353201, 435455, 424 932, 4241301, 536 235

Abstract:

Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34. 5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid having a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-. A method of expressing in a mammalian cell a gene encoding a preselected protein, a method of treating a genetic defect, and a method of detecting an HSV-1 expressing cell also employ vectors of the present invention that contain at least one transcriptional unit of a constitutive LAT promoter operatively linked to and controlling the transcription of a gene encoding a preselected protein.

US Patent:

6838279, Jan 4, 2005

Filed:

Oct 29, 2001

Appl. No.:

10/046491

Inventors:

Steven L. Wechsler - Westlake Village CA, US
Anthony B. Nesburn - Malibu CA, US
John S. Yu - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A61K 4800
C12N 1563
C12N 1587
C12N 500

US Classification:

4353201, 435325, 435455, 435456, 435 691, 514 44, 4241991

Abstract:

Disclosed is an HSV-1-derived vector containing a DNA having a functional LAT promoter, or operative fragment thereof, a deletion in both copies of the HSV-1 LAT gene, and a deletion in both copies of the HSV-1 ICP34. 5 gene. The HSV-1-derived vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid encoding a preselected protein. In some embodiments, the preselected protein is a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-γ. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, and mammalian cells containing the HSV-derived vectors.

US Patent:

6930222, Aug 16, 2005

Filed:

Aug 22, 2001

Appl. No.:

09/935386

Inventors:

John C. Yu - La Jolla CA, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A01K067/00
A01K067/033

US Classification:

800 10, 800 8, 800 9

Abstract:

The present invention provides a process for making an in vivo model of human leukemia. The process includes the steps of: pre-conditioning an immunodeficient rodent by administering to the rodent a sub-lethal dose of irradiation and injecting the rodent with an effective pre-conditioning amount of human fetal cord blood mononuclear cells; maintaining the rodent for from about 5 to 10 days; and injecting the rodent with an effective engrafting amount of primary human leukemia cells. An in vivo and in vitro model of human leukemia are also provided.

US Patent:

7129034, Oct 31, 2006

Filed:

Sep 24, 2002

Appl. No.:

10/253759

Inventors:

John S. Yu - Los Angeles CA, US
Peter Kabos - Los Angeles CA, US
Moneeb Ehtesham - Nashville TN, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

C12N 5/00
C12N 5/06
C12N 5/08
C12N 5/10

US Classification:

435 11, 435377, 435372, 435325, 435368

Abstract:

A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.

US Patent:

7504100, Mar 17, 2009

Filed:

Feb 28, 2006

Appl. No.:

11/364394

Inventors:

John S. Yu - Los Angeles CA, US
Peter Kabos - Los Angeles CA, US
Moneeb Ehtesham - Nashville TN, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A61K 48/00

US Classification:

424 9321, 424 931, 424 932, 435325

Abstract:

A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.

US Patent:

7899916, Mar 1, 2011

Filed:

Sep 30, 2003

Appl. No.:

10/677090

Inventors:

David Bumstead - San Jose CA, US
John Burns - Los Altos CA, US
Fong Liaw - San Jose CA, US
Jan Medved - Pleasanton CA, US
John Z. Yu - Santa Clara CA, US

Assignee:

Brixham Solutions Ltd. - Tortola

International Classification:

G06F 15/16

US Classification:

709228, 709227, 709231

Abstract:

A system and method are disclosed for establishing a connection between a first endpoint participating in a first protocol and a second endpoint participating in a second protocol. Establishing a connection includes establishing a virtual service endpoint participating in the first protocol on a network device that is connected to the first endpoint and the second endpoint and forwarding to the second endpoint communication directed from the first endpoint to the virtual service endpoint.

US Patent:

7970009, Jun 28, 2011

Filed:

Aug 21, 2003

Appl. No.:

10/646340

Inventors:

Fong Liaw - Cupertino CA, US
Jan Medved - Pleasanton CA, US
Abbas Morshed - Los Altos CA, US
Yijun Xiong - Plano TX, US
John Z. Yu - Santa Clara CA, US

Assignee:

Brixham Solutions Ltd. - Tortola

International Classification:

H04J 3/22

US Classification:

370466, 370469

Abstract:

A system and method are disclosed for processing a packet. Processing the packet comprises receiving the packet; translating the packet from a first protocol-specific format to a canonical packet format; translating the packet from the canonical packet format to a second protocol-specific format; and forwarding the packet.

US Patent:

8071366, Dec 6, 2011

Filed:

May 15, 2006

Appl. No.:

11/433996

Inventors:

John S. Yu - Los Angeles CA, US
Peter Kabos - Los Angeles CA, US
Moneeb Ehtesham - Nashville TN, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

C12N 5/0797
C12N 5/074

US Classification:

435325, 435372, 435377, 435368

Abstract:

A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.